"Based on the clinical response observed in our 28-day Phase 1 study in rosacea patients, we believe this Phase 2 rosacea study will further elucidate the anti-inflammatory and anti-redness properties of DMT210," states Chris Nardo, VP, Development of Dermata. "Working upstream and downstream in the skin's inflammatory process, DMT210 blocks TLR-2 and GPCR (G-protein coupled receptor) signaling, thus potentially inhibiting the IL-6, IL-8 and TNF-a expression in skin of rosacea patients. Unlike other currently marketed rosacea products, DMT210 has the potential to reduce inflammatory lesions as well as the redness associated with rosacea."
About Rosacea: Rosacea is a chronic, inflammatory skin disorder of the facial region that is estimated to affect 13 to 14 million individuals in the United States. Rosacea's onset typically begins around age 30 and gets progressively worse if left untreated. The disease is characterized by erythema (redness), telangiectasia, flushing, papules, pustules, ocular redness, and rhinophyma.
About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-announces-initiation-of-treatment-in-a-phase-2-acne-rosacea-clinical-study-300392811.html
SOURCE Dermata Therapeutics, LLC